Get started
Author

Denise Lau

Observed name: Lau, Denise
ORCID: 0000-0001-8924-0171
Observed ORCID: 0000-0001-8924-0171
OpenAlex ID: A5069507828
Clinical validation of the tempus xT next-generation targeted oncology sequencing assay
2019 · Nike Beaubier, Robert Tell, et al. · Oncotarget · 244
PDF
Integrated genomic profiling expands clinical options for patients with cancer
2019 · Nike Beaubier, Martin Bontrager, et al. · Nature Biotechnology · 187
Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures
2022 · Kabir Mody, Prerna Jain, et al. · JCO Precision Oncology · 70
Clinical validation of the Tempus xO assay
2018 · Nike Beaubier, Robert Tell, et al. · Oncotarget · 62
PDF
RNA Sequencing of the Tumor Microenvironment in Precision Cancer Immunotherapy
2019 · Denise Lau, Alexandria M. Bobe, et al. · Trends in cancer · 48
Integration of tumor extrinsic and intrinsic features associates with immunotherapy response in non-small cell lung cancer
2022 · Denise Lau, Sonal Khare, et al. · Nature Communications · 29
PDF
Tumor mutational burden and other predictive immunotherapy markers in histiocytic neoplasms
2019 · Gaurav Goyal, Denise Lau, et al. · Blood · 29
PDF
Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).
2019 · Sean Khozin, Mark S. Walker, et al. · Journal of Clinical Oncology · 16
Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer
2022 · Yinjie Gao, Michelle M. Stein, et al. · Cancer Immunology Immunotherapy · 13
PDF
Integrating RNA expression and visual features for immune infiltrate prediction
2018 · Derek Reiman, Lingdao Sha, et al. · Pacific Symposium on Biocomputing (PSB) · 11
Real-world prevalence of autoimmune disease (AD) among patients (pts) receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ database.
2019 · Li Chen, Mark S. Walker, et al. · Journal of Clinical Oncology · 6
Multimodal profiling of biliary tract cancers to detect potentially actionable biomarkers and differences in immune signatures between subtypes.
2021 · Kabir Mody, Nilofer Saba Azad, et al. · Journal of Clinical Oncology · 4
Next generation sequencing (NGS) to identify relapsed gastrointestinal (GI) solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) for future logic-gated CAR T therapy to reduce on target off tumor toxicity.
2022 · J. Randolph Randolph Hecht, Scott Kopetz, et al. · Journal of Clinical Oncology · 3
181 Associations between multimodal immune biomarkers and clinical outcomes in a real-world non-small cell lung cancer cohort
2023 · Michelle M Stein, Mario Rosasco, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
Real-world characteristics and outcomes of patients with advanced non-small cell lung cancer (aNSCLC) receiving immune checkpoint inhibitor.
2019 · Sean Khozin, Jizu Zhi, et al. · Journal of Clinical Oncology · 1
Characteristics of patients receiving immune checkpoint inhibitors (ICI) in ASCO’s CancerLinQ.
2019 · Wendy S. Rubinstein, Li Chen, et al. · Journal of Clinical Oncology · 1
73 Characterization of tumor-infiltrating T-cell repertoire in human cancers
2021 · Taylor Harding, Qidi Yang, et al. · Regular and Young Investigator Award Abstracts
PDF
Abstract 1487: Cytotoxic CD4+ T cells contribute to anti-tumor immune responses in NSCLC
2021 · Denise Lau, Sonal Khare, et al. · Cancer Research
Abstract 1616: Characterizing differences in checkpoint inhibitor biomarkers in a real-world cohort of stage III and IV non-small cell lung cancer patients
2021 · Yinjie Gao, Michelle M. Stein, et al. · Cancer Research
Abstract 773: Evaluating clinical features and prognostic factors associated with response to immune checkpoint blockade in mNSCLC patients
2021 · Prerna Jain, Michelle Stein, et al. · Cancer Research
Abstract B57: Integrating RNA expression and visual features for immune infiltrate prediction
2020 · Derek Reiman, Lingdao Sha, et al. · Cancer Immunology Research
Abstract PR12: Genomic landscape of immunotherapy resistance in lung cancer
2020 · Denise Lau, Michelle Stein, et al. · Cancer Immunology Research
Abstract 135: Predicting oncogenic viral status using RNA signatures
2019 · Ariane Lozac’hmeur, Denise Lau, et al. · Cancer Research
Survey of the immunogenomic landscape of solid tumors through clinical DNA and RNA sequencing.
2019 · Denise Lau, Alan Chang, et al. · Journal of Clinical Oncology
Early Memory B Cells in Humans are Primed for Plasma Cell Differentiation and are Refractory to Reactivation
2016 · Lau, Denise · Knowledge@UChicago (University of Chicago)
Works count: 25
Citation count: 725
H-index: 10
I10-index: 10
Year
Topic
Type